Ejim Mark, MD, MPH, MBA

Self Employed
Boston, Massachusetts, United States

Ejim Mark is the Global Medical Unit Head Autoimmune diseases/Rheumatology at Takeda Pharmaceuticals.

Presentation(s):

• 1155: Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): Takeda Pharmaceuticals: Employee (Ongoing)